

1 **Adapting COVID-19 research infrastructure to capture influenza and**  
2 **respiratory syncytial virus alongside SARS-CoV-2 in UK healthcare**  
3 **workers winter 2022/23: Results of a pilot study in the SIREN cohort**

4 **Authors:** Sarah Foulkes<sup>1†\*</sup>, Katie Munro<sup>1†</sup>, Dominic Sparkes<sup>1</sup>, Jonathan Broad<sup>1</sup>, Naomi  
5 Platt<sup>1</sup>, Anna Howells<sup>1</sup>, Omolola Akinbami<sup>1</sup>, Jameel Khawam<sup>1</sup>, Palak Joshi<sup>1</sup>, Sophie Russell<sup>1</sup>,  
6 Chris Norman<sup>2</sup>, Lesley Price<sup>3</sup>, Diane Corrigan<sup>4</sup>, Michelle Cole<sup>1</sup>, Jean Timelin<sup>1</sup>, Louise  
7 Forster<sup>1</sup>, Katrina Slater<sup>1</sup>, Conall H Watson<sup>1</sup>, Nick Andrews<sup>1</sup>, Andre Charlett<sup>1</sup>, SIREN study  
8 group<sup>^</sup>, Ana Atti<sup>1</sup>, Jasmin Islam<sup>1</sup>, Colin S Brown<sup>1</sup>, Jonathan Turner<sup>1</sup>, Susan Hopkins<sup>1</sup>,  
9 Victoria Hall<sup>1</sup>

10 <sup>†</sup>These authors contributed equally to this work.

11 **Affiliations:**

12 1: United Kingdom Health Security Agency (UKHSA), 10 South Colonnade, Canary Wharf,  
13 London, United Kingdom, E14 4PU

14 2: Health and Care Research Wales, 5 15, Castlebridge, 19 Cowbridge Rd E, Cardiff CF11  
15 9AB

16 3: Public Health Scotland, Meridian Court, 5 Cadogan Street, Glasgow, United Kingdom, G2  
17 6QE

18 4: Health and Social Care in Northern Ireland (HSC), 12-22 Linenhall Street, Belfast, United  
19 Kingdom, BT2 8BS

20

21 **\*Corresponding author**

22 Email: Sarah.Foulkes@UKHSA.gov.uk

23

24 <sup>^</sup>Members of SIREN study group included in supplementary material

25 **NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.**

## 26 **ABSTRACT**

### 27 Introduction

28 The combination of patient illness and staff absence driven by seasonal viruses culminates  
29 in annual “winter pressures” on UK healthcare systems and has been exacerbated by  
30 COVID-19. In winter 2022/23 we ran a pilot study aiming to introduce multiplex testing to  
31 determine the incidence and burden of SARS-CoV-2, influenza and respiratory syncytial  
32 virus (RSV) in our cohort of UK healthcare workers (HCWs).

### 33 Methods

34 The pilot study was conducted from 28/11/2022-31/03/2023 within the SIREN prospective  
35 cohort study. Participants completed fortnightly questionnaires, capturing symptoms and sick  
36 leave, and multiplex PCR testing for SARS-CoV-2, influenza and RSV, regardless of  
37 symptoms. PCR-positivity rates by virus were calculated over time, and viruses were  
38 compared by symptoms and severity. Self-reported symptoms and associated sick leave  
39 were described. Sick leave rates were compared by vaccination status and demographics.

### 40 Results

41 5,863 participants were included, 84.6% female, 70.3% ≥45-years, and 33.4% were nurses.  
42 PCR-positivity peaked in early December for all three viruses (4.6 positives per 100 tests  
43 (95%CI 3.5, 5.7) SARS-CoV-2, 3.9 (95%CI 2.2, 5.6) influenza, 1.4 (95%CI 0.4, 2.4) RSV),  
44 declining to <0.3/100 tests after January for influenza/RSV, and around 2.5/100 tests for  
45 SARS-CoV-2. Over one-third of all infections were asymptomatic, and symptoms were  
46 similar for all viruses. 1,368 (23.3%) participants reported taking sick leave, median 4 days  
47 (range 1-59). Rates of sick leave were higher in participants with co-morbidities, working in  
48 clinical settings, and who had not been vaccinated (COVID-19 booster or seasonal influenza  
49 vaccine) versus those who had received neither vaccine (2.04 vs 1.41 sick days/100 days,  
50 adjusted Incidence Rate Ratio 1.47 (95%CI 1.38, 1.56).

51 Conclusion

52 This pilot demonstrated the use of multiplex testing allowed better understanding of the  
53 impact of seasonal respiratory viruses and respective vaccines on the HCW workforce. This  
54 highlights the important information on asymptomatic infection and persisting levels of  
55 SARS-CoV-2 infection.

56

57

58

59

60

61

62

63

64

65

66

67

68

69

70

71

## 72 INTRODUCTION

73 UK healthcare systems experience significant challenges each winter, due to the impact of  
74 seasonal surges in respiratory viruses, including influenza and respiratory syncytial virus  
75 (RSV), which combined are often described as “winter pressures” (1, 2). Respiratory illness  
76 increases patient attendance but also causes significant staff absence, with respiratory  
77 illness the second most common cause of sick leave within the NHS (3). Reduction in staff  
78 sickness absence and preventing nosocomial transmission are the rationale for the annual  
79 NHS winter flu vaccine campaign for healthcare workers (HCW) and the prioritisation of  
80 HCW for COVID-19 vaccine boosters (4, 5).

81 As a result of the pandemic, COVID-19 has been well characterised in relation to key  
82 scientific and clinical questions including the role of antibodies as correlates of protection,  
83 rates of asymptomatic disease and real-world vaccine effectiveness (6-11). However, this is  
84 not the case for the other principle seasonal viruses, influenza and RSV, where the focus  
85 has been on symptomatic disease and in populations most at risk, including children and the  
86 elderly (12, 13). HCWs are an important population to study given the impact of respiratory  
87 illnesses on the workforce and their high exposure (14, 15), offering insights into the natural  
88 history, epidemiology and burden of influenza and RSV in working aged populations.

89 The SARS-CoV-2 Immunity and Reinfection Evaluation (SIREN) study is a prospective  
90 cohort study of HCWs across the UK, with participants completing regular SARS-CoV-2  
91 PCR testing and antibody testing continuously since June 2020 (16). It was set up at the  
92 start of the pandemic to assess the risk of re-infection with SARS-CoV-2 and has continued  
93 to adapt to address key scientific questions.

94 During the COVID-19 pandemic, the introduction of non-pharmaceutical measures, including  
95 universal masking and social distancing, was found to reduce the rates of other respiratory  
96 viruses (4, 17). However, following the removal of these interventions, the winter of 2022/23  
97 was the first opportunity to understand the impact of circulating seasonal viruses on the NHS

98 workforce. Therefore, in winter 2022/23 the SIREN study piloted a “Winter Pressures sub-  
99 study” that included multiplex PCR testing for influenza and RSV alongside SARS-CoV-2  
100 (18).

101 This paper outlines the results of the SIREN Winter Pressures Pilot study 2022/23, with the  
102 aim of a) describing the burden of influenza (A and B), RSV, and SARS-CoV-2, b)  
103 characterisation of SIREN HCW symptom profile, and c) understanding time off work due to  
104 being symptomatic in the context of HCW vaccination.

105

## 106 **METHODS**

### 107 **Study design**

108 The SIREN Winter Pressures sub-study is a prospective cohort study nested within the  
109 SIREN UK multicentre HCW cohort study (16, 18).

### 110 **Participants**

111 Participants were recruited into the sub-study via two routes: 1) participants previously  
112 completing monoplex testing (for SARS-CoV-2 only) were informed, in writing, before the  
113 sub-study start date (28 November 2022) that testing would move to multiplex testing  
114 (SARS-CoV-2, Influenza and RSV), and were given the opportunity to withdraw from the  
115 study; 2) additional participants were re-recruited (from participants who were not currently  
116 testing) and consented directly into the winter pressures postal testing pathway, between 13  
117 December 2022 and 24 January 2023 (18).

118 Participants undergoing PCR testing between 28 November 2022 and 31 March 2023 were  
119 included in the sub-study. Participants contributed different lengths of time to the analysis  
120 period, due to completing study follow-up time or withdrawing from the study.

121

122

## 123 **Data collection**

124 Participants completed fortnightly questionnaires on symptoms (onset date, type and  
125 duration) and related time taken-off work due to reported symptoms, in addition to an  
126 enrolment survey at the start of the SIREN study, detailing the participant's demographics,  
127 occupation, underlying medical conditions and household composition. Vaccination data  
128 (COVID-19 and seasonal influenza vaccination) was obtained both from the fortnightly  
129 questionnaire and linkage to national vaccination registries.

130 Participants completed swabs for either multiplex PCR (SARS-CoV-2, influenza and where  
131 available RSV) or monoplex PCR (SARS-CoV-2 only), fortnightly regardless of symptoms.  
132 PCR testing, symptoms and sociodemographic data were linked via a unique study ID.

## 133 **Variables**

134 We defined participants who reported at least one of any of the following symptoms as being  
135 symptomatic: cough, fever, shortness of breath, sore throat, runny nose, headache, muscle  
136 aches, altered sense of smell or taste, fatigue, diarrhoea, nausea or vomiting, itchy red  
137 patches on fingers or toes, rash, swollen glands (19). Influenza-like illness (ILI) was defined  
138 as participants reporting fever and at least one of following: cough, sore throat, shortness of  
139 breath, headache, muscle ache or fatigue. For this analysis, COVID-19 vaccination refers to  
140 receiving the second booster dose of the COVID-19 vaccine, and influenza vaccination  
141 refers to receiving the 2022/23 seasonal influenza vaccine between 01 September 2022 and  
142 31 March 2023. Sick leave was defined as any self-reported days off work due to being  
143 symptomatic.

## 144 **Outcomes**

145 The co-primary outcomes were a) a PCR-positive test for either SARS-CoV-2, influenza or  
146 RSV; b) proportion of participants reporting ILI symptoms; and c) the number of days taken  
147 off work due to being symptomatic.

148

149 **Inclusion criteria**

150 Participants who completed at least one fortnightly questionnaire and at least one PCR test  
151 during the analysis period were included.

152 **Statistical analysis**

153 Participants' sociodemographic and occupational characteristics were described.

154 Infection rates by pathogen were calculated over time. Samples were initially de-duplicated  
155 resulting in one test per fortnight per participant, prioritising a positive sample over a  
156 negative sample in the same fortnight. Samples which were positive for multiple viruses  
157 were excluded from the analysis. Further de-duplication by infection episode meant that for  
158 SARS-CoV-2, participants could only have one positive sample per 90 days. For influenza  
159 and RSV, participants could only have one positive sample per 30 days.

160 For the infection analysis, participants were considered vaccinated if they had received the  
161 seasonal vaccine dose at least 14 days before the first positive PCR sample of the infection  
162 episode.

163 An infection was considered symptomatic if the participant had reported a symptom onset  
164 date seven days pre or post the date of first positive PCR sample for each infection episode.

165 The proportion of participants with each infection was summarised by sociodemographic  
166 characteristics and vaccination status. Symptom type, number, duration, hospital  
167 attendance and time off work were compared by infection and vaccination status (SARS-  
168 CoV-2 and influenza only) using proportions.

169 The proportion of participants reporting ILI symptoms was calculated over time, by dividing  
170 the number of surveys where ILI was reported by the total number of surveys in each time  
171 period.

172 Sick leave rate was calculated by fortnight, using the number of days taken off work divided  
173 by the number of days participants contributed to the analysis period, per 100 days, with

174 95% confidence interval. Incidence rate ratio were calculated to estimate demographic  
175 factors associated with taking time off work, unadjusted and adjusted (vaccination status,  
176 age, occupational setting and co-morbidities).

177 For sick leave rate by vaccination status, participants contributed days to the vaccinated  
178 state (COVID-19 and influenza separately or simultaneously) if they had received the  
179 vaccine at least 14 days before the start of the fortnightly survey period. Participants  
180 contributed days to the unvaccinated state if they had not received the seasonal dose or had  
181 received the dose after the end of the survey period. For participants who received either  
182 vaccine within a survey period, or within the 14 days prior to the survey start date, this  
183 survey period did not count towards the rate analysis.

184

## 185 **RESULTS**

186 A total of 7,774 participants consented to the SIREN Winter Pressures pilot sub-study from  
187 28 November 2022 to 31 March 2023. Of these, 5,863 (75.4%) participants had both survey  
188 and testing data and were included in the analysis (Fig 1). Most participants were female  
189 (84.6%), of white ethnicity (91.4%), over 45-years of age (70.3%); nursing was the largest  
190 staff group (33.4%). Study participants were highly vaccinated, with 74.2% receiving both  
191 COVID-19 and the seasonal influenza vaccine (Table 1).

192

193 **Fig 1: Flow diagram describing participants included in the SIREN Winter Pressures**  
194 **pilot sub-study**

195

196

197



198 **Table 1: Demographics of participants included in the analysis, overall and by**  
199 **infection (SARS-CoV-2, Influenza and RSV), 28 November 2022 to 31 March 2023**

<b>Characteristic</b>	<b>All participants n (%)</b>	<b>SARS-CoV-2 positive N (%)</b>	<b>Influenza positive n (%)</b>	<b>RSV positive n (%)</b>
<b>Total</b>	<b>5,863</b>	<b>643</b>	<b>91</b>	<b>74</b>
<b>Age group</b>				
Under 25	39 (0.7)	1 (0.2)	1 (1.1)	3 (4.1)
25 to 34	447 (7.6)	56 (8.7)	11 (12.1)	2 (2.7)
35 to 44	1,257 (21.4)	151 (23.5)	24 (26.4)	13 (17.6)
45 to 54	2,280 (38.9)	244 (37.9)	30 (33.0)	36 (48.6)
55 to 64	1,690 (28.8)	173 (26.9)	23 (25.3)	20 (27.0)
Over 65	150 (2.6)	18 (2.8)	2 (2.2)	0 (0.0)
<b>Gender</b>				
Female	4,960 (84.6)	541 (84.1)	67 (73.6)	64 (86.5)
Male	896 (15.3)	101 (15.7)	24 (26.4)	9 (12.2)
Non-binary	4 (0.1)	1 (0.2)	0 (0.0)	1 (1.4)
Prefer not to say	3 (0.1)	0 (0.0)	0 (0.0)	0 (0.0)
<b>Ethnicity</b>				
White	5,359 (91.4)	594 (92.4)	85 (93.4)	70 (94.6)
Asian	272 (4.6)	30 (4.7)	4 (4.4)	3 (4.1)
Black	94 (1.6)	5 (0.8)	0 (0.0)	0 (0.0)
Mixed Race	70 (1.2)	6 (0.9)	1 (1.1)	1 (1.4)
Other Ethnic Group	52 (0.9)	4 (0.6)	1 (1.1)	0 (0.0)
Prefer not to say	16 (0.3)	4 (0.6)	0 (0.0)	0 (0.0)
<b>Medical condition</b>				
Chronic respiratory conditions	738 (12.6)	75 (11.7)	13 (14.3)	8 (10.8)
Chronic non-respiratory conditions	679 (11.6)	76 (11.8)	8 (8.8)	13 (17.6)
Immunosuppression	128 (2.2)	16 (2.5)	2 (2.2)	1 (1.4)
No medical condition	4,318 (73.6)	476 (74.0)	68 (74.7)	52 (70.3)
<b>Household</b>				
Lives alone	683 (11.6)	82 (12.8)	11 (12.1)	9 (12.2)
Lives with adults	3,010 (51.3)	325 (50.5)	42 (46.2)	30 (40.5)
Lives with children	2,170 (37.0)	236 (36.7)	38 (41.8)	35 (47.3)
<b>Staff type</b>				
Nursing	1,957 (33.4)	221 (34.4)	22 (24.2)	21 (28.4)
Administrative/Executive	1,014 (17.3)	95 (14.8)	14 (15.4)	11 (14.9)
Doctor	670 (11.4)	67 (10.4)	12 (13.2)	14 (18.9)
Healthcare Assistant	360 (6.1)	53 (8.2)	3 (3.3)	2 (2.7)
Healthcare Scientist	279 (4.8)	32 (5.0)	7 (7.7)	5 (6.8)
Student	175 (3.0)	25 (3.9)	3 (3.3)	1 (1.4)
Physiotherapist/Occupational Therapist/SALT	228 (3.9)	33 (5.1)	10 (11.0)	4 (5.4)
Midwife	133 (2.3)	12 (1.9)	3 (3.3)	1 (1.4)
Pharmacist	129 (2.2)	16 (2.5)	3 (3.3)	2 (2.7)
Estates/Porters/Security	113 (1.9)	8 (1.2)	3 (3.3)	1 (1.4)
Other	805 (13.7)	81 (12.6)	11 (12.1)	12 (16.2)
<b>Occupation setting</b>				
Office	1,333 (22.7)	135 (21.0)	26 (28.6)	11 (14.9)
Outpatient	1,213 (20.7)	135 (21.0)	19 (20.9)	18 (24.3)
Inpatient Wards	671 (11.4)	89 (13.8)	9 (9.9)	13 (17.6)
Patient facing (non-clinical)	273 (4.7)	29 (4.5)	2 (2.2)	8 (10.8)
Intensive Care	208 (3.5)	30 (4.7)	4 (4.4)	4 (5.4)
Theatres	152 (2.6)	22 (3.4)	2 (2.2)	5 (6.8)
Ambulance/Emergency Department	108 (1.8)	12 (1.9)	4 (4.4)	2 (2.7)
Maternity/Labour Ward	82 (1.4)	7 (1.1)	1 (1.1)	1 (1.4)
Other	1,823 (31.1)	184 (28.6)	24 (26.4)	12 (16.2)

Characteristic	All participants n (%)	SARS-CoV-2 positive N (%)	Influenza positive n (%)	RSV positive n (%)
<b>Patient contact</b>				
Yes	4,841 (82.6)	535 (83.2)	75 (82.4)	71 (95.9)
No	1,022 (17.4)	108 (16.8)	16 (17.6)	3 (4.1)
<b>Vaccination status</b>				
Both	4,349 (74.2)	481 (74.8)	62 (68.1)	54 (73.0)
Influenza 2022/23 vaccine only	499 (8.5)	53 (8.2)	8 (8.8)	5 (6.8)
COVID-19 second booster dose only	354 (6.0)	28 (4.4)	10 (11.0)	5 (6.8)
Neither	661 (11.3)	81 (12.6)	11 (12.1)	10 (13.5)

200 *Note: Eight participants had multiple infections during the analysis period – four participants had a SARS-CoV-2*  
 201 *and an influenza infection, three had influenza and RSV, and one had SARS-CoV-2 and RSV.*

202

203 **SARS-CoV-2, influenza and RSV infection rates over winter 2022/23**

204 All 5,863 participants were tested for SARS-CoV-2, 4,689 (80.0%) for influenza and 4,695  
 205 (80.0%) for RSV. Of these, 643/5,863 (11.0%) participants had a positive SARS-CoV-2  
 206 result, 93/4,689 (2.0%) had a positive influenza result and 74/4,695 (1.6%) had a positive  
 207 RSV result.

208 PCR positivity rates for all three viruses peaked in early December 2022 (peak positive PCR  
 209 per 100 tests: 4.6 (95% CI 3.5, 5.7) for SARS-CoV-2, 3.9 (95% CI 2.2, 5.6) influenza, 1.4  
 210 (95% CI 0.4, 2.4) RSV), with influenza and RSV decreasing to low levels after January 2023  
 211 (for influenza  $\leq 0.2$  and RSV  $\leq 0.3$  positives per 100 tests), whereas SARS-CoV-2 maintained  
 212 rates around 2.5 per 100 tests until March 2023 (Fi 2).

213

214 **Fig 2: PCR positivity rate (per 100 tests) by fortnight and infection, 28 November 2022**  
 215 **to 31 March 2023**

216 *Note: shaded areas represent 95% confidence intervals*

217

218

219

220 **Influenza-like illness symptoms over winter 2022/23**

221 There were 4,003 (68.3%) participants who reported symptoms over the analysis period,  
222 with 1,054 (18.0%) reporting ILI symptoms. The proportion of participants reporting ILI  
223 symptoms by fortnight peaked in early December 2022 (peak fortnight was 7.5% (95% CI  
224 6.8, 8.3) (368/4,893 surveys) (Fig 3).

225

226 **Fig 3: Proportion of participants reporting influenza-like illness symptoms by**  
227 **fortnight, 28 November 2022 to 31 March 2023**

228 *Shaded areas represent 95% confidence intervals*

229

230 **Symptom profile by SARS-CoV-2, influenza and RSV**

231 The proportion of asymptomatic infections were similar among the three viruses – influenza  
232 (45.6%), SARS-CoV-2 (41.7%) and RSV (37.5%). Symptom profiles were similar for all three  
233 viruses. Although, loss of sense of smell and taste were more common among those with an  
234 SARS-CoV-2 infection and fever more common with a influenza infection. Hospital  
235 attendance was low for all viruses (Table 2).

236

237

238

239

240

241

242 **Table 2: Description of the symptom profile and severity of SARS-CoV-2, influenza**  
 243 **and RSV PCR positive infections, 28 November 2022 to 31 March 2023**

	<b>SARS-CoV-2 n (%)</b>	<b>Influenza n (%)</b>	<b>RSV n (%)</b>	<i>p-value (SARS- CoV-2 vs influenza)</i>	<i>p-value (SARS-CoV-2 vs RSV)</i>	<i>p-value (RSV vs influenza)</i>
<b>Total</b>	<b>643</b>	<b>93</b>	<b>74</b>			
<b>Symptoms</b>				<i>0.494</i>	<i>0.594</i>	<i>0.327</i>
Any symptoms	346 (58.3)	49 (54.4)	40 (62.5)			
Asymptomatic	247 (41.7)	41 (45.6)	24 (37.5)			
<b>Symptoms type</b>						
Loss of smell	67 (11.3)	3 (3.3)	4 (6.3)	<i>0.015</i>	<i>0.289</i>	<i>0.45</i>
Cough	182 (30.7)	33 (36.7)	17 (26.6)	<i>0.274</i>	<i>0.568</i>	<i>0.223</i>
Diarrhoea	37 (6.2)	5 (5.6)	2 (3.1)	<i>&gt;0.999</i>	<i>0.414</i>	<i>0.7</i>
Loss of taste	80 (13.5)	3 (3.3)	4 (6.3)	<i>0.005</i>	<i>0.116</i>	<i>0.45</i>
Fatigue	160 (27.0)	24 (26.7)	13 (20.3)	<i>&gt;0.999</i>	<i>0.297</i>	<i>0.445</i>
Fever	105 (17.7)	25 (27.8)	9 (14.1)	<i>0.03</i>	<i>0.602</i>	<i>0.05</i>
Swollen glands	45 (7.6)	6 (6.7)	1 (1.6)	<i>&gt;0.999</i>	<i>0.074</i>	<i>0.24</i>
Headache	228 (38.4)	29 (32.2)	24 (37.5)	<i>0.294</i>	<i>&gt;0.999</i>	<i>0.606</i>
Muscle aches	179 (30.2)	24 (26.7)	13 (20.3)	<i>0.538</i>	<i>0.112</i>	<i>0.445</i>
Runny nose	258 (43.5)	33 (36.7)	28 (43.8)	<i>0.253</i>	<i>&gt;0.999</i>	<i>0.406</i>
Shortness of breath	87 (14.7)	12 (13.3)	13 (20.3)	<i>0.873</i>	<i>0.27</i>	<i>0.273</i>
Sore throat	231 (39.0)	39 (43.3)	29 (45.3)	<i>0.488</i>	<i>0.348</i>	<i>0.87</i>
Vomiting	38 (6.4)	8 (8.9)	5 (7.8)	<i>0.368</i>	<i>0.598</i>	<i>&gt;0.999</i>
<b>Duration of symptoms</b>				<i>0.09</i>	<i>0.405</i>	<i>0.729</i>
1-3	43 (12.6)	1 (2.0)	2 (5.0)			
4-6	79 (23.2)	10 (20.4)	8 (20.0)			
7-14	54 (15.9)	8 (16.3)	9 (22.5)			
>14	164 (48.2)	30 (61.2)	21 (52.5)			
<b>Sick leave</b>				<i>0.002</i>	<i>0.868</i>	<i>0.049</i>
Taken	180 (52.2)	14 (28.6)	20 (50.0)			
Not taken	165 (47.8)	35 (71.4)	20 (50.0)			
<b>Number of sick leave taken (days)</b>				<i>0.015</i>	<i>0.484</i>	<i>0.079</i>
1-3	67 (37.2)	9 (64.3)	10 (50.0)			
4-6	56 (31.1)	5 (35.7)	4 (20.0)			
7-14	57 (31.7)	0 (0.0)	6 (30.0)			
<b>Hospital attendance</b>				<i>0.358</i>	<i>0.095</i>	<i>0.654</i>
Yes	8 (2.3)	2 (4.1)	3 (7.5)			
No	338 (97.7)	47 (95.9)	37 (92.5)			

244

245

246 **Time off work due to being symptomatic over winter 2022/23**

247 Of participants testing positive for SARS-CoV-2 and RSV, ≥50% of participants reported  
 248 taking time off work for being symptomatic (52.2% and 50.0%, respectively), compared to  
 249 28.6% for influenza infections (Table 2). The median number of days taken off work for a  
 250 SARS-CoV-2 infection was 5 (IQR: 2-7); 3 days (IQR: 2.25-5) for influenza and 4 days (IQR:  
 251 2-7) for RSV.

252 Over the analysis period, a total of 1,368/5,863 (23.3%) participants reported taking time off  
 253 work due to being symptomatic; taking a median of 4 days off over the analysis period  
 254 (range: 1-59 days). Of participants reporting ILI symptoms, 616/1,054 (58.4%) reported  
 255 taking time off work; taking a median of 5 days; range: 1-59 days.

256 The 5,863 participants included contributed to a total of 507,388 follow-up days during the  
 257 winter period. The rate of sick leave over this period was 1.48 days per 100 days of follow-  
 258 up, with the peak seen in early December 2022 (2.4 days per 100 days) (Fig 4).

259

260 **Fig 4: Rate of sick leave taken (per 100 days) by fortnight, 28 November 2022 to 31**  
 261 **March 2023**

262 *Note: Sick leave rate was calculated as number of sick leave days taken divided by the*  
 263 *number of days participants contributed to the analysis period, per 100 days; Shaded areas*  
 264 *represent 95% confidence intervals*

265

266 **Factors associated with taking time off work**

267 Participants who took time off work due to being symptomatic between November 2022 and  
 268 March 2023 appeared to differ by occupational setting, long-term medical conditions and  
 269 vaccination status (Table 3).

270 **Table 3: Factors associated with time off work due to being symptomatic, 28**  
 271 **November 2022 to 31 March 2023**

Characteristic	Sick leave rate <sup>b</sup> (95% CI)	IRR (95% CI)	Adjusted IRR (95% CI)
<b>Vaccination status <sup>a</sup></b>			
Both COVID-19 second booster and Influenza 2022/23 vaccine	1.41 (1.37, 1.45)	Ref	Ref
Influenza 2022/23 Vaccine	1.52 (1.40, 1.65)	1.08 (0.99, 1.17)	1.04 (0.95, 1.13)
COVID-19 second booster dose	1.26 (1.14, 1.40)	0.90 (0.81, 1.0)	0.91 (0.82, 1.02)
Neither vaccine	2.04 (1.93, 2.16)	1.45 (1.36, 1.54)	1.47 (1.38, 1.56)

<b>Age group</b>			
Under 25	1.55 (1.10, 2.16)	Ref	Ref
25 to 34	1.84 (1.69, 1.99)	1.19 (0.85, 1.66)	1.16 (0.83, 1.63)
35 to 44	1.51 (1.44, 1.59)	0.98 (0.70, 1.36)	0.92 (0.66, 1.28)
45 to 54	1.49 (1.43, 1.54)	0.96 (0.69, 1.33)	0.91 (0.65, 1.26)
55 to 64	1.44 (1.38, 1.50)	0.93 (0.67, 1.29)	0.89 (0.64, 1.24)
Over 65	0.69 (0.56, 0.84)	0.44 (0.30, 0.65)	0.45 (0.30, 0.66)
<b>Occupation setting</b>			
Theatres	2.13 (1.89, 2.40)	1.91 (1.68, 2.18)	1.89 (1.66, 2.15)
Intensive Care	1.91 (1.72, 2.13)	1.72 (1.52, 1.94)	1.74 (1.54, 1.96)
Outpatient	1.62 (1.55, 1.70)	1.45 (1.35, 1.56)	1.49 (1.39, 1.60)
Ambulance/Emergency Department	1.58 (1.33, 1.86)	1.42 (1.19, 1.69)	1.36 (1.14, 1.62)
Maternity/Labour Ward	1.58 (1.30, 1.92)	1.42 (1.16, 1.73)	1.38 (1.13, 1.68)
Inpatient Wards	1.57 (1.47, 1.67)	1.41 (1.29, 1.53)	1.36 (1.25, 1.49)
Patient facing (non-clinical)	1.53 (1.38, 1.70)	1.38 (1.23, 1.55)	1.40 (1.25, 1.57)
Other	1.50 (1.44, 1.56)	1.35 (1.26, 1.44)	1.38 (1.29, 1.47)
Office	1.11 (1.05, 1.18)	Ref	Ref
<b>Medical group</b>			
No medical condition	1.29 (1.26, 1.33)	Ref	Ref
Immunosuppression	2.71 (2.42, 3.03)	2.09 (1.86, 2.35)	2.19 (1.95, 2.46)
Chronic Respiratory conditions	2.01 (1.90, 2.12)	1.55 (1.46, 1.65)	1.60 (1.50, 1.70)
Chronic Non-Respiratory conditions	1.87 (1.77, 1.99)	1.45 (1.36, 1.55)	1.52 (1.42, 1.63)

272 <sup>a</sup> Participants were excluded if they were vaccinated in one survey period and unvaccinated in another survey  
273 period. Surveys were excluded from the analysis if the participant was vaccinated within the survey date range. <sup>b</sup>  
274 Sick leave rate was calculated as number of sick leave days taken divided by the number of days participants  
275 contributed to the analysis period, per 100 days. IRR = Incidence rate ratio. CI = Confidence interval

276

277 Participants in office-based roles took less time off work (1.11 days per 100 days) when  
278 compared to clinical roles such as theatres and intensive care units (2.13 and 1.91 days per  
279 100 days, respectively. Estimated from adjusted Incidence Rate Ratios (IRR) also show this;  
280 theatres (1.89; 95% CI 1.66, 2.15) and intensive care units (1.74; 95% CI 1.54, 1.96) verses  
281 office-based participants. Participants with immunosuppressive, chronic respiratory and  
282 chronic non-respiratory conditions took more time off work than participants with no reported  
283 comorbidities (who took off 1.29 days per 100 days): immunosuppressive conditions 2.71  
284 days per 100, adjusted IRR 2.19 (95% CI 1.95, 12.46); chronic respiratory 2.01/100 days,

285 adjusted IRR 1.60 (95% CI 1.50, 1.70); and chronic non-respiratory conditions 1.87/100  
286 days, adjusted IRR 1.52 (95% CI 1.42, 1.63).

287 Those who were vaccinated against both influenza and COVID-19 took less time off work  
288 (1.41 days per 100 days) than those who did not receive either vaccine (2.04 days per 100  
289 days) (Table 3). After controlling for age, occupational setting and co-morbidities, we  
290 estimated that those who received neither vaccine had a 47% higher rate of sick leave than  
291 those vaccinated for both (adjusted IRR 1.47 (95% CI 1.38, 1.56)).

292

## 293 **DISCUSSION**

294 Results from the 2022/23 SIREN Winter Pressures pilot study demonstrate the impact of  
295 respiratory illness on the NHS workforce. Rates of SARS-CoV-2, influenza and RSV, and  
296 symptoms, all peaked in early December, resulting in increased levels of sickness absence  
297 over this time period.

298 The PCR positivity trends over winter 2022/23 in our cohort of HCW is consistent with national  
299 surveillance data (17) demonstrating the potential utility of conducting surveillance in this  
300 population to determine the prevalence and impact of respiratory viral infections in the working  
301 age population (20). Our detection of RSV infections in this population, which is rarely tested  
302 for this virus, suggests that RSV also contributes to winter pressures. The finding that  
303 symptom profiles were similar across the three viruses is consistent with existing published  
304 literature (21). Across all three viruses, a substantial proportion of infections were  
305 asymptomatic but could potentially contribute to transmission, in particular, influenza with over  
306 two-thirds of infections asymptomatic (22). This highlights the potential risk associated with  
307 nosocomial infections in healthcare workers, though we do not have strong evidence how  
308 transmissible asymptomatic infections is. The impact of respiratory illness on time off work in  
309 our cohort of HCW over winter 2022/23 was considerable, with 23% of participants reporting  
310 time off work due to being symptomatic, and all three viruses contributing to this. Sick leave

311 rates varied by demographics and vaccination status, with lower estimated rates among those  
312 who received the second COVID-19 booster and seasonal influenza vaccine. Given the impact  
313 that HCW time off work could have on healthcare resilience over winter, further research into  
314 associated factors, including behaviours and attitudes, is important.

315 A key limitation of this pilot study was the coverage and timing of multiplex PCR roll-out. There  
316 were fewer participants with PCR results for influenza and RSV than those with a SARS-CoV-2  
317 test result. In this pilot, multiplex testing was introduced late in the winter season, with testing  
318 data only available from late November 2022, due to delays switching PCR platforms across  
319 NHS laboratories (using a decentralised study testing model), and the timing of establishing a  
320 new centralised postal PCR pathway. This delay was compounded by an unusually early  
321 influenza season in 2022/23 (17). Consequently, our surveillance of these viruses over winter  
322 2022/23 may have missed some infections within our cohort, particularly influenza and RSV.

323 This pilot sub-study conducted during winter 2022/23 has demonstrated the adaptability and  
324 applicability of findings from the SIREN HCW cohort. Results from the study show the  
325 benefit of regular multiplex testing across NHS Trusts to understand the interplay and impact  
326 of seasonal viruses on workforce planning, patient care and healthcare resilience in the NHS  
327 during the Winter. We have demonstrated that all three viruses contribute to staff illness and  
328 time off work over winter, and that seasonal flu and COVID-19 vaccines were associated  
329 with lower sick leave rates. Future studies should consider using a centralised multiplex  
330 testing pathway to improve surveillance of respiratory infections and ensure the timing of  
331 testing is optimised.

332

333

334

335



## 336 **ACKNOWLEDGEMENTS**

337 Our thanks go to the participants in the SIREN study. We would also like to thank the help  
338 and support offered by the Berkshire Research Ethics Committee and the HDR-UK for winter  
339 pressures funding and to UKHSA for core SIREN study funding. Thanks also to all research  
340 team and site staff not mentioned above.

341

## 342 **REFERENCES**

- 343 1. Elliot AJ, Cross KW, Fleming DM. Acute respiratory infections and winter pressures  
344 on hospital admissions in England and Wales 1990-2005. *J Public Health (Oxf)*.  
345 2008;30(1):91-8.
- 346 2. Mahase E. NHS England announces "data driven war rooms" to tackle winter  
347 pressures. *BMJ*. 2022;379:o2515.
- 348 3. NHS Sickness Absence Interactive Dashboard [Internet]. 2024 [cited 06/02/2024].  
349 Available from:  
350 <https://app.powerbi.com/view?r=eyJrljoiYTY3MjE0NmEtYzY2Yi00MmY4LTg4NDQzZTM2ZTI5YjZiOGMyliwidCI6IjUwZjYwNzFmLWJiZmUtNDAxYS04ODAzLTY3Mzc0OGU2MjllMjllMmMlOj9>  
351 [5YjZiOGMyliwidCI6IjUwZjYwNzFmLWJiZmUtNDAxYS04ODAzLTY3Mzc0OGU2MjllMjllMmMlOj9](#)  
352 [iOjh9](#).
- 353 4. UKHSA. Influenza: the green book, chapter 19. In: UKHSA, editor. *The Green Book*.  
354 gov.uk2023. p. 18.
- 355 5. UKHSA. Immunisation of healthcare and laboratory staff: the green book, chapter 12.  
356 In: UKHSA, editor. *The Green Book*. gov.uk: UKHSA; 2013. p. 1-8.
- 357 6. Atti A, Insalata F, Carr EJ, Otter AD, Foulkes S, Wu MY, et al. Antibody correlates of  
358 protection against Delta infection after vaccination: A nested case-control within the UK-  
359 based SIREN study. *J Infect*. 2023;87(5):420-7.
- 360 7. Regev-Yochay G, Lustig Y, Joseph G, Gilboa M, Barda N, Gens I, et al. Correlates of  
361 protection against COVID-19 infection and intensity of symptomatic disease in vaccinated

- 362 individuals exposed to SARS-CoV-2 in households in Israel (ICoFS): a prospective cohort  
363 study. *Lancet Microbe*. 2023;4(5):e309-e18.
- 364 8. Ma Q, Liu J, Liu Q, Kang L, Liu R, Jing W, et al. Global Percentage of Asymptomatic  
365 SARS-CoV-2 Infections Among the Tested Population and Individuals With Confirmed  
366 COVID-19 Diagnosis: A Systematic Review and Meta-analysis. *JAMA Netw Open*.  
367 2021;4(12):e2137257.
- 368 9. Hall V, Foulkes S, Insalata F, Saei A, Kirwan P, Atti A, et al. Effectiveness and  
369 durability of protection against future SARS-CoV-2 infection conferred by COVID-19  
370 vaccination and previous infection; findings from the UK SIREN prospective cohort study of  
371 healthcare workers March 2020 to September 2021. *medRxiv*. 2021:2021.11.29.21267006.
- 372 10. Kirwan PD, Hall VJ, Foulkes S, Otter AD, Munro K, Sparkes D, et al. Effect of second  
373 booster vaccinations and prior infection against SARS-CoV-2 in the UK SIREN healthcare  
374 worker cohort. *Lancet Reg Health Eur*. 2024;36:100809.
- 375 11. Huiberts AJ, de Gier B, Hoeve CE, de Melker HE, Hahne SJ, den Hartog G, et al.  
376 Effectiveness of bivalent mRNA booster vaccination against SARS-CoV-2 Omicron infection,  
377 the Netherlands, September to December 2022. *Euro Surveill*. 2023;28(7).
- 378 12. Riccio MD, Spreeuwenberg P, Osei-Yeboah R, Johannesen CK, Fernandez LV,  
379 Teirlinck AC, et al. Defining the Burden of Disease of RSV in Europe: estimates of RSV-  
380 associated hospitalisations in children under 5 years of age. A systematic review and  
381 modelling study. *medRxiv*. 2023:2023.02.10.23285756.
- 382 13. Coultas JA, Smyth R, Openshaw PJ. Respiratory syncytial virus (RSV): a scourge  
383 from infancy to old age. *Thorax*. 2019;74(10):986-93.
- 384 14. Vargese SS, Dev SS, Soman AS, Kurian N, Varghese VA, Mathew E. Exposure risk  
385 and COVID-19 infection among frontline health-care workers: A single tertiary care centre  
386 experience. *Clin Epidemiol Glob Health*. 2022;13:100933.
- 387 15. Macintyre CR, Seale H, Yang P, Zhang Y, Shi W, Almatroudi A, et al. Quantifying the  
388 risk of respiratory infection in healthcare workers performing high-risk procedures. *Epidemiol  
389 Infect*. 2014;142(9):1802-8.

- 390 16. Wallace S, Hall V, Charlett A, Kirwan PD, Cole M, Gillson N, et al. Impact of prior  
391 SARS-CoV-2 infection and COVID-19 vaccination on the subsequent incidence of COVID-  
392 19: a multicentre prospective cohort study among UK healthcare workers - the SIREN  
393 (Sarscov2 Immunity & REinfection EvaluationN) study protocol. *BMJ Open*.  
394 2022;12(6):e054336.
- 395 17. UKHSA. National Influenza and COVID-19 surveillance report. .gov.uk; 2023.
- 396 18. Broad J, Sparkes D, Platt N, Howells A, Foulkes S, Khawam J, et al. Adapting  
397 COVID-19 research infrastructure to capture influenza and respiratory syncytial virus  
398 alongside SARS-CoV-2 in UK healthcare workers winter 2022/23 and beyond: protocol for a  
399 pragmatic sub-study [version 1; peer review: awaiting peer review]. *NIHR Open Research*.  
400 2024;4(1).
- 401 19. UKHSA. SIREN Follow-up Questionnaire v6.1. 2022.
- 402 20. Foulkes S, Monk EJM, Sparkes D, Hettiarachchi N, Milligan ID, Munro K, et al. Early  
403 Warning Surveillance for SARS-CoV-2 Omicron Variants, United Kingdom, November 2021-  
404 September 2022. *Emerg Infect Dis*. 2023;29(1):184-8.
- 405 21. Ma X, Conrad T, Alchikh M, Reiche J, Schweiger B, Rath B. Can we distinguish  
406 respiratory viral infections based on clinical features? A prospective pediatric cohort  
407 compared to systematic literature review. *Rev Med Virol*. 2018;28(5):e1997.
- 408 22. Cohen C, Kleynhans J, Moyes J, McMorrow ML, Treurnicht FK, Helfferscee O, et al.  
409 Asymptomatic transmission and high community burden of seasonal influenza in an urban  
410 and a rural community in South Africa, 2017-18 (PHIRST): a population cohort study. *Lancet*  
411 *Glob Health*. 2021;9(6):e863-e74.
- 412

**7,774**  
participants consented  
to the study

<https://doi.org/10.1101/2024.12.09.24318698>  
(which was not certified by peer review)  
It is made available under a [CC-BY 4.0 International license](#)

18 participants withdrawn  
and requested data to be  
removed from the study

917 participants did  
not complete a follow-  
up survey

1,789 participants did  
not complete a PCR  
test


**6,839** participants  
with survey data

**5,967** participants  
with testing data


**5,863** participants  
with survey and testing  
data

Figure 1

### SARS-CoV-2



### Influenza



### RSV




Figure2




Figure3




Figure4